GHRP-2 Dosage Guide: Reconstitution, Half-Life & GH Secretagogue Research Protocol

GHRP-2 research protocol: 100–300 mcg dosing, ghrelin receptor agonism, 30-min half-life, reconstitution table, and comparison with ipamorelin for GH research.

TL;DR

• GHRP-2 is a synthetic hexapeptide ghrelin receptor (GHSR-1a) agonist that stimulates GH pulses from the pituitary
• Research doses: 100–300 mcg per injection; saturation occurs above 300 mcg
• Half-life: ~30 minutes; GH pulse duration ~90–120 minutes
• Compared to ipamorelin: GHRP-2 has broader ghrelin pathway effects including cortisol and hunger stimulation
• Best stacked with a GHRH analog (CJC-1295 or sermorelin) for synergistic GH release

Disclaimer: For educational and research purposes only — not medical advice.

GHRP-2 (Growth Hormone-Releasing Peptide-2) is one of the most-studied synthetic GH secretagogues in the research literature, serving both as a pharmacological tool for investigating the ghrelin receptor system and as a functional GH stimulant in preclinical and early-phase clinical research. Its role as the gold-standard compound in the GHRP-2 stimulation test — a widely used clinical diagnostic for GH deficiency — gives it a level of clinical validation that many research peptides lack. This guide covers everything needed to design a GHRP-2 research protocol from reconstitution through dosing strategy.

Ghrelin Receptor Agonism: How GHRP-2 Releases GH

GHRP-2 (hexapeptide, also known as Pralmorelin) is a synthetic six-amino-acid peptide that acts as an agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a). This receptor is the endogenous ghrelin receptor — the target of the "hunger hormone" ghrelin, an acylated 28-amino-acid peptide produced primarily in the gastric fundus.

The GH-releasing mechanism of GHRP-2 operates via a pathway distinct from GHRH. Upon GHSR-1a activation by GHRP-2, intracellular signaling proceeds through Gq/G11-mediated phospholipase C activation → IP3 generation → intracellular calcium release → protein kinase C activation → GH granule exocytosis from anterior pituitary somatotrophs. This calcium-dependent pathway is complementary to the adenylate cyclase/cAMP pathway activated by GHRH receptor stimulation.

This mechanistic complementarity explains why GHRP-2 and GHRH analogs produce synergistic GH release when co-administered. Studies by Bowers et al. and others have demonstrated that the combined GH pulse from simultaneous GHRH + GHRP administration can be 3-5x greater than either compound alone — a fundamental principle of GH secretagogue stack design.

GHRP-2 also exerts effects at the hypothalamic level, suppressing somatostatin release (the primary GH inhibitory peptide). This dual action — pituitary stimulation + hypothalamic somatostatin suppression — makes GHRP-2's GH-releasing mechanism especially potent.

Dosage Parameters and Receptor Saturation

GHRP-2's dose-response relationship is non-linear due to receptor saturation at the somatotroph level. Published data from multiple studies establishes a practical ceiling for GH release from GHRP-2 alone:

• 100 mcg: Standard diagnostic dose (GHRP-2 stimulation test). Produces a clear, measurable GH pulse. Cortisol and prolactin elevation minimal at this dose.
• 150–200 mcg: Common research dose for GH secretagogue studies. Good GH pulse amplitude with manageable off-target effects.
• 300 mcg: Near-maximal GH release from GHRP-2 alone. Increasing above this threshold produces diminishing GH returns while increasing ghrelin-mediated side effects (hunger, cortisol, prolactin).

For most research applications examining GH pulse characteristics, 100–200 mcg is the dose range with the most favorable signal-to-noise profile. When combined with a GHRH analog (CJC-1295 or sermorelin), the effective GH output from 100 mcg GHRP-2 approximates what would require 300+ mcg of GHRP-2 alone.

Use the dosage calculator to determine injection volumes for any GHRP-2 concentration, and the reconstitution calculator for vial preparation.

Reconstitution Table and Storage Protocol

GHRP-2 is supplied as a lyophilized powder, typically in 2 mg or 5 mg vials. It is reconstituted with bacteriostatic water (BW) for multi-use vials or sterile water for single-use preparation.

Storage: Unreconstituted lyophilized GHRP-2 is stable at room temperature for short periods but should be stored at -20°C for long-term storage. Once reconstituted with bacteriostatic water, store at 2-8°C and use within 28 days. Avoid freeze-thaw cycling of reconstituted solution.

Injection technique: Subcutaneous injection in the lower abdominal area 30 minutes before the relevant research window (pre-sleep, pre-exercise, or upon waking) using a 27-29 gauge insulin syringe.

GHRP-2 vs Ipamorelin: Choosing the Right GHRP

The comparison between GHRP-2 and ipamorelin is central to GH secretagogue research design. Both are GHSR-1a agonists, but their receptor selectivity profiles diverge meaningfully.

GHRP-2 is a "dirty" GHRP in the sense that GHSR-1a activation through GHRP-2 produces downstream effects beyond GH secretion: cortisol elevation (+18–35% in some studies at 200+ mcg doses), prolactin elevation, and ACTH stimulation. Hunger stimulation is pronounced due to GHRP-2's structural similarity to acylated ghrelin. These off-target effects are not necessarily problematic — for researchers studying ghrelin receptor biology, cardiovascular effects, or appetite regulation, they may be the point.

Ipamorelin was specifically engineered for selectivity. Its GHSR-1a activation at research doses (100–300 mcg) produces minimal cortisol, prolactin, or ACTH changes — making it the preferred choice when clean GH pulse studies are the objective. Hunger stimulation with ipamorelin is notably blunted compared to GHRP-2.

For research stacking with CJC-1295, ipamorelin is generally preferred for its clean profile, while GHRP-2 is valuable when studying the full ghrelin receptor signaling cascade. See also the GHRP-2 database entry for compound-specific reference data.

Frequently Asked Questions

Q: What is the standard research dose for GHRP-2? A: Published research protocols use 100–300 mcg per injection subcutaneously or intravenously. The 100 mcg dose is the established standard for the GHRP-2 stimulation test (clinical GH reserve diagnostic). GH output increases with dose up to approximately 300 mcg, above which receptor saturation limits further release while off-target ghrelin effects (hunger, cortisol) continue increasing. For most research applications, 100–200 mcg provides the best signal-to-noise ratio. When co-administered with a GHRH analog, the effective dose can be reduced while maintaining or increasing GH pulse amplitude through synergistic mechanisms.

Q: How does GHRP-2 differ from ipamorelin? A: Both are GHSR-1a agonists that stimulate GH pulses, but their selectivity profiles differ significantly. GHRP-2 produces moderate cortisol, prolactin, and ACTH elevation at doses above 100–150 mcg, and strong hunger stimulation through the ghrelin pathway. Ipamorelin was specifically designed to minimize these off-target effects — it produces GH release with minimal cortisol, prolactin, or appetite effects. For research requiring clean GH pulse quantification without endocrine confounders, ipamorelin is preferred. GHRP-2's broader ghrelin pathway activity makes it useful for ghrelin receptor pharmacology studies.

Q: How do you reconstitute a GHRP-2 vial? A: A standard 5 mg vial reconstituted with 2.5 mL bacteriostatic water yields 2 mcg/mcL. A 100 mcg dose requires 50 mcL (0.05 mL on a 1 mL insulin syringe). For easier measurement at standard research doses, 5 mL BW in a 5 mg vial gives 1 mcg/mcL — a 100 mcg dose then requires 100 mcL (0.10 mL). Store reconstituted solution at 2-8°C and use within 28 days. Use the reconstitution calculator to generate exact volumes for any vial size and target dose.

Q: What is GHRP-2's half-life and how does it affect dosing timing? A: GHRP-2 has a half-life of approximately 30 minutes, producing a GH pulse lasting roughly 90–120 minutes. Multi-injection research protocols typically use 2–3 injections daily aligned with physiological GH release windows: upon waking (natural GH nadir transitioning to morning pulse), pre-exercise (for exercise-induced GH synergy), and pre-sleep (the largest natural GH pulse window). The pre-sleep injection is generally considered the highest-priority timing in recovery-focused protocols, coinciding with the GH pulse that drives overnight tissue repair.

Research Tools → Reconstitution Calculator → Dosage Calculator → Half-Life Calculator → GHRP-2 Database Entry

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions